A Demand Notice paper publication has been issued to the Company by Hinduja Leyland Finance Limited for the default in outstanding term loan provided by them
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has disclosed that Hinduja Leyland Finance Limited, an NBFC, has classified the company's term loans as a Non-Performing Asset (NPA) due to non-payment of principal and interest installments. A SARFAESI Demand Notice was published on 30 January 2026, with the date of default recorded as 26 December 2025. The outstanding amount is Rs. 6.46 crore as a direct borrower and an additional Rs. 19.12 crore as a co-borrower along with seven other co-borrowers, with a sanctioned principal of Rs. 6.5 crore and Rs. 19.5 crore respectively at 13% interest, secured. The company's total borrowings from banks and financial institutions stand at Rs. 41 crore, with total financial indebtedness of Rs. 54.48 crore. The company stated it is evaluating the notice and will take steps to regularize the accounts and protect stakeholder interests.
This is a significant negative development — the NPA classification and SARFAESI notice indicate serious financial distress, potential recovery action by the lender, and heightened credit risk for shareholders. The stock could see negative sentiment and pressure given the scale of the default relative to the company's overall debt profile.